Abstract
Human mitochondrial DNA (mtDNA) polymerase γ (Pol γ) is the only polymerase known to replicate the mitochondrial genome. The Pol γ holoenzyme consists of the p140 catalytic subunit (POLG) and the p55 homodimeric accessory subunit (POLG2), which enhances binding of Pol γ to DNA and promotes processivity of the holoenzyme. Mutations within POLG impede maintenance of mtDNA and cause mitochondrial diseases. Two common POLG mutations usually found in cis in patients primarily with progressive external ophthalmoplegia generate T251I and P587L amino acid substitutions. To determine whether T251I or P587L is the primary pathogenic allele or whether both substitutions are required to cause disease, we overproduced and purified WT, T251I, P587L, and T251I + P587L double variant forms of recombinant Pol γ. Biochemical characterization of these variants revealed impaired DNA binding affinity, reduced thermostability, diminished exonuclease activity, defective catalytic activity, and compromised DNA processivity, even in the presence of the p55 accessory subunit. However, physical association with p55 was unperturbed, suggesting intersubunit affinities similar to WT. Notably, although the single mutants were similarly impaired, a dramatic synergistic effect was found for the double mutant across all parameters. In conclusion, our analyses suggest that individually both T251I and P587L substitutions functionally impair Pol γ, with greater pathogenicity predicted for the single P587L variant. Combining T251I and P587L induces extreme thermal lability and leads to synergistic nucleotide and DNA binding defects, which severely impair catalytic activity and correlate with presentation of disease in patients.
Keywords: DNA polymerase, DNA replication, mitochondrial disease, mitochondrial DNA (mtDNA), mitochondrial DNA damage, mitochondrial DNA mutations, mitochondrial DNA replication, progressive external ophthalmoplegia
Introduction
Human mitochondrial DNA (mtDNA)2 is replicated and repaired by DNA polymerase γ (Pol γ), which consists of a 140-kDa catalytic subunit (encoded by POLG at nuclear chromosomal locus 15q25) and a 55-kDa accessory subunit that forms a dimer (encoded by POLG2 at nuclear chromosomal locus 17q24.1) (1–3). The catalytic subunit contains the N-terminal exonuclease domain connected by a linker region to the C-terminal polymerase domain. The catalytic subunit has DNA polymerase, 3′ → 5′ exonuclease, and 5′-deoxyribose phosphate lyase activities (4, 5). The accessory subunit functions to enhance polymerase processivity by increasing affinity of the catalytic subunit for DNA (6–8).
Deletions and point mutations in mtDNA as well as depletion of mtDNA are associated with several mitochondrial disorders and aging (9–11). Many of these deleterious effects on mtDNA are caused by defects in the nuclear genes encoding mtDNA replication proteins, such as POLG. To date, over 300 disease-associated mutations in POLG are listed in the Human DNA Polymerase Gamma Mutation Database. Mitochondrial diseases broadly vary and include progressive external ophthalmoplegia (PEO), Alpers syndrome, ataxia neuropathy syndrome (ANS), myocerebrohepatopathy spectrum disorders, myoclonus epilepsy myopathy sensory ataxia, parkinsonism, and male infertility (12–15). In general, all tissues/organs are susceptible, but tissues with a large oxygen consumption, such as skeletal muscle, heart, and brain, are particularly vulnerable. Further, the severity of phenotypic expression and the age at which the disease first presents itself can be unpredictable.
Among unrelated families harboring two mutant POLG alleles, the most common mutations are A467T (∼31%), G848S (∼10%), and W748S (∼8%), followed by in cis T251I + P587L (∼6%) (15). With the exception of T251I + P587L, all have been previously characterized biochemically to provide insight into the consequence and mechanism of these Pol γ mutations. Located in the linker region between the exonuclease and polymerase domains of Pol γ, the A467T mutation is associated with PEO, Alpers, and ANS. The purified recombinant A467T Pol γ protein possesses diminished DNA polymerase activity (4% of the wild type) and disrupted interaction with the p55 accessory subunit (16). The G848S mutation changes a highly conserved residue in the polymerase thumb subdomain that causes Alpers syndrome. In vitro biochemical studies show reduced DNA polymerase activity (<1% of WT) and a 5-fold reduction in DNA binding affinity as compared with the wild-type (WT) protein (17). Linked to Alpers syndrome and ANS is the W748S mutation in the linker region of Pol γ. The recombinant W748S Pol γ exhibits low DNA polymerase activity, processivity, and affinity for DNA (18). These defects can be modulated by the common E1143G single nucleotide polymorphism (SNP), which is almost always found in cis with W748S (18). This outcome strongly suggests that the presence of other in cis mutations could alter the function of Pol γ for better or worse.
Scuderi et al. (19) recently compiled a comprehensive list of clinical phenotypes and genetic characteristics of the approximately 50 cases of T251I + P587L mentioned in the literature. The main clinical presentation is PEO, with or without ptosis, and secondary clinical features include ataxia, myopathy, epilepsy, neuropathy, and hepatic diseases. Age of onset is variable, and disease is equally distributed between the sexes. Alpers and myocerebrohepatopathy spectrum disorders have been diagnosed in infancy, although infrequently (20).
The T251I and P587L substitutions are located in the exonuclease domain and linker region of the Pol γ gene, respectively (Fig. 1A). Each exists at the same frequency in any given database, ranging from 0.30 to 0.52% of the worldwide population. Even more dramatically, the in cis T251I + P587L mutation pair was reported in heterozygosity with a wild-type allele in ∼1% of Italian controls (21, 22). In patients, the in cis T251I + P587L mutation pair is found either on both alleles (22–24) or, more frequently, as a compound heterozygous mutation pair in trans with another putative pathogenic mutation (15, 20, 21, 24–28). Three previous studies have reported T251I as a compound heterozygote without P587L (29–31). However, resequencing of Pol γ in the first two cases revealed that T251I was actually in cis with P587L (32). Conversely, P587L as a compound heterozygote without T251I has been documented in three patients with PEO (33–35). PolyPhen-2, a publicly available computer algorithm that predicts the impact of an amino acid substitution on the structure and function of a protein, projected P587L as probably damaging and T251I as benign. This may be due in part to the higher phylogenetic conservation of P587L as compared with T251I (Fig. 1B) and the presence of two known pathogenic mutations, G588D and P589L, near P587L (36). Given these data, it has been predicted that P587L is the pathogenic allele (20, 22). Nonetheless, because both mutations are found in almost all clinical cases, definitive assignment of pathogenicity to T251I or P587L and/or possible synergistic effects has remained uncertain until now. In this work, we biochemically characterized the individual (WT, T251I, and P587L) and combination (T251I + P587L) human Pol γ variants along several parameters, including intrinsic affinity for double-stranded DNA, thermostability, steady-state kinetics analysis of polymerase and exonuclease activities, physical association with the p55 accessory subunit, and processivity of DNA synthesis. Our results demonstrate not only functional impairment of each of the individual variants on Pol γ, but a dramatic synergistic effect, thus exposing the underlying molecular mechanism.
FIGURE 1.
Identification of human DNA Pol γ mutations. A, schematic diagram of motifs I, II, and III in the exonuclease domain; the linker region; and motifs A, B, and C in the polymerase domain. The T251I mutation is located in the exonuclease domain, whereas the P587L mutation is in the linker region. B, phylogenetic conservation of POLG codons 251 and 587 across species.
Results
Production of Pol γ Variants
To study the biochemical properties of the individual T251I and P587L Pol γ variants and the combination variant in comparison with WT, we created each substitution employing site-directed mutagenesis, overexpressed the recombinant proteins in baculovirus-infected Sf9 cells, and purified each to homogeneity following established purification processes (37–39). Immunoblot analysis confirmed the identity of each full-length variant. The overall yields of WT and each individual variant were equivalent but were less than previously reported for the exonuclease-deficient WT Pol γ (37). However, the yield of the T251I + P587L combination variant was significantly less, although predictable chromatographic behavior during purification and SDS-PAGE analysis showed purity and structural integrity of all enzymes (data not shown).
DNA Binding Affinity Is Impaired for the Pol γ Variants
Mutations in the Pol γ polymerase domain and linker region have resulted in impaired binding to DNA (17, 18, 38). Hence, the DNA binding affinity of the WT and Pol γ variants was measured by EMSA. Various concentrations of each enzyme were incubated with a fluorescently labeled 54-bp, double-stranded, forked oligonucleotide substrate, and the mixtures were resolved by native PAGE to separate the protein-DNA complex from free DNA (Fig. 2, A–D). Of note are the two distinct shifted species for bound DNA in all variants with the exception of T251I + P587L. Each species is dependent on the concentration of the enzyme and may reflect two areas of DNA binding. The apparent dissociation constant, Kd(DNA), for each variant was calculated by fitting the fraction of DNA bound as a function of enzyme concentration to a quadratic equation by non-linear regression analysis with compensation for ligand depletion (Fig. 2E) (40). Both WT and T251I had strong affinities for DNA at 72.5 ± 10.7 and 60.5 ± 12.2 nm, respectively (Fig. 2F). P587L affinity for DNA was moderately, yet significantly, compromised with a 2-fold reduction as compared with WT (138.9 ± 10.1 nm). Similarly, the binding affinity of T251I + P587L for DNA was even more impaired with a ∼3-fold reduction from WT (200.5 ± 16.3 nm) (Fig. 2F).
FIGURE 2.
Diminished DNA binding affinity in the Pol γ variants. Native polyacrylamide gels for EMSAs to measure DNA binding affinities are shown for WT (A), T251I (B), P587L (C), and T251I + P587L (D) Pol γ variants. Lanes correspond to enzyme concentrations as follows: 0 nm (lane 1), 12.5 nm (lane 2), 25 nm (lane 3), 50 nm (lane 4), 75 nm (lane 5), 100 nm (lane 6), 105 nm (lane 7), 125 nm (lane 8), 150 nm (lane 9), 175 nm (lane 10), 200 nm (lane 11), 225 nm (lane 12), 250 nm (lane 13). E, binding isotherms plot the fraction of DNA bound at enzyme concentrations ranging from zero to the highest attainable concentration for each enzyme in the absence of p55, including an inset providing a closer view of the T251I + P587L binding data. Red circles, WT; blue squares, T251I; orange diamonds, P587L; purple triangles, T251I + P587L. F, apparent Kd(DNA) values as calculated by non-linear regression analysis of the plot shown in E using KaleidaGraph (Synergy Software). All values are the average of three independent experiments with error expressed as S.D. and significance determined by Student's t test. *, p ≤ 0.05.
Thermostability of the Pol γ Variants Is Reduced
Pol γ activities are extremely sensitive to heat inactivation, particularly in the absence of a DNA substrate (16, 41). Although intrinsic protein stability of the α-helices within Pol γ variants has been gauged previously by circular dichroism spectroscopy (17, 18, 39), heat inactivation of the holoenzyme (p140 + p55) followed by its functional assessment in the presence of a primer-template limits determination of protein stability to only active molecules in the protein population. Consequently, we heat-inactivated each holoenzyme variant (1 nm p140 + 2 nm p55) by incubation at 37 °C at several time points between 0 and 45 min and then measured reverse transcriptase activity in 10-min reactions using poly(rA)·oligo(dT)12–18 as the primer-template (see “Experimental Procedures”). WT was inactivated with a half-life of 7.5 ± 0.8 min (Fig. 3, A and B). T251I, P587L, and T251I + P587L each had significantly lower half-lives at 5.7 ± 0.4, 3.6 ± 0.2, and 2.1 ± 0.2 min, respectively (Fig. 3, A and B). The significant reduction in half-life for the Pol γ variants indicates that these amino acid substitutions promote a higher probability of losing activity through heat-induced conformational change that causes unrecoverable loss of activity, and this effect is additive for the combination mutant.
FIGURE 3.

Pol γ variants exhibit higher heat lability than WT. Each holozyme variant (1 nm p140 + 2 nm p55) was heated at 37 °C for 0, 1, 2, 3, 4, 5, 6, 7.5, 9, 13, 17, 21, 25, 30, 35, 40, or 45 min and then assessed functionally with a 10-min reverse transcriptase activity assay using poly(rA)·oligo(dT)12–18 as the primer-template. A, the graph of percentage activity over time is shown with time 0 set as 100% for each variant. Red circles, WT; blue squares, T251I; orange diamonds, P587L; purple triangles, T251I + P587L. B, half-life in minutes for each variant estimated from the graph is given where each variant is significantly less than WT. All values are the average of three or more independent experiments with error expressed as S.D. and significance determined by Student's t test. *, p ≤ 0.05.
Exonuclease Activities of the Pol γ Variants Are Diminished
Because one of the mutations resides within the exonuclease domain, exonuclease activity was determined by monitoring degradation of the 5′-end-labeled 35-mer single-stranded M13 DNA primer by 12% urea-PAGE denaturing gel (see “Experimental Procedures”). The rate of excising 3′-primer termini for each enzyme was determined by plotting the loss of substrate versus time at points along a 3-min reaction. Final enzyme concentrations were experimentally determined to be within the linear range of the reaction for each variant. A representative gel revealing nucleotide excision events with the plot of exonuclease product formed as a function of time for the Pol γ variants is shown (Fig. 4, A–E). The turnover number (kexo) for WT exonuclease activity was 20.9 ± 1.0 min−1 (Fig. 4F). The T251I substitution in the exonuclease domain of Pol γ resulted in a 7.2-fold reduction (2.9 ± 0.3 min−1) in exonuclease activity. Although P587L is in the linker region, kexo for P587L was reduced 3.4-fold (6.2 ± 0.4 min−1). Excision by the double mutant form was severely impaired by 13.1-fold (1.6 ± 0.4 min−1), suggesting synergistic defects for the T251I + P587L variant (Fig. 4F).
FIGURE 4.

Exonuclease activities of all Pol γ variants are severely disrupted. A representative 12% urea-polyacrylamide gel monitoring degradation of ssDNA over increasing time is shown for 0.3 nm WT (A), 1.25 nm T251I (B), 1.50 nm P587L (C), and 3.0 nm T251I + P587L (D). Lanes correspond to reaction time as follows: 0 min (lane 1), 0.5 min (lane 2), 1 min (lane 3), 1.5 min (lane 4), 2 min (lane 5), 2.5 min (lane 6), and 3 min (lane 7). The different enzyme concentrations used for each protein were experimentally determined to be within the linear range of the reaction and are indicated. E, plot of exonuclease product formed over time during the linear range of the reaction for the gel. Red circles, 0.3 nm WT; blue squares, 1.25 nm T251I; orange diamonds, 1.50 nm P587L; purple triangles, 3.0 nm T251I + P587L. F, a scatter plot of exonuclease turnover number (kexo) for each enzyme. All values are the average of six or more independent experiments with error expressed as S.D. and significance determined by Student's t test. *, p ≤ 0.05.
Kinetic Parameters of the Pol γ Variants Reveal Catalytic Defects
Steady-state kinetic measurements for the Pol γ variants in the presence of p55 were determined in a standard DNA synthesis assay utilizing the homopolymeric primer-template substrate poly(dA)·oligo(dT)12–18 with Mg2+ as cofactor and with varying concentrations of dTTP. The rate of dTTP incorporated over time was used to calculate Km(dTTP) and kcat by fitting the data to the steady-state Michaelis-Menten model (Fig. 5A). The WT enzyme had a Km(dTTP) of 1.1 ± 0.1 μm and a kcat of 8.0 ± 0.6 min−1 (Table 1), in accordance with values that have been reported previously (18, 42). The efficacy of each enzyme can be estimated by the specificity constant, kcat/Km(dTTP), which is equivalent to the pre-steady-state indicator of enzymatic efficiency, kpol/Kd (17, 43, 44). For ease of comparison, specificity constants for mutant enzymes were also expressed as a fraction of the WT value. For example, the catalytic efficiencies for the single variants T251I and P587L were similar at 29 and 32% of WT activity, respectively (Table 1). We were unable to attain kinetic parameters for the T251I + P587L variant without using higher dTTP concentrations (Fig. 5B). Despite this, the double mutant demonstrated severe catalytic dysfunction and retained only 5% of WT activity.
FIGURE 5.

Catalytic defects are evident in all of the Pol γ variants with extreme deficiency in the double mutant. A, a representative Michaelis-Menten saturation curve for all the Pol γ variants used to calculate kinetic parameters. Red circles, WT; blue squares, T251I; orange diamonds, P587L; purple triangles, T251I + P587L. B, representative Michaelis-Menten plot for T251I + P587L at higher dTTP concentrations. All graphs are representative of three independent experiments.
TABLE 1.
Steady-state kinetic parameters of WT and Pol γ variants
Km(dTTP) and kcat were determined for the holoenzymes with poly(dA)-oligo(dT)12–18 as the primer-template under 100 mm NaCl as described under “Experimental Procedures.” All kinetic parameters were determined by nonlinear regression analysis of the data presented in Fig. 5. The average of three independent experiments is shown with error expressed as S.D. and significance determined by Student's t test.
| Pol γ enzyme | Km(dTTP) | kcat | kcat/Km(dTTP) | Activity |
|---|---|---|---|---|
| μm | min−1 | min−1 μm−1 | % | |
| WT | 1.1 ± 0.1 | 8.0 ± 0.6 | 7.2 ± 0.6 | 100 |
| T251I | 2.0 ± 1.2a | 3.4 ± 0.2a | 2.1 ± 1.0a | 29a |
| P587L | 2.5 ± 0.5a | 5.6 ± 1.9a | 2.3 ± 1.0a | 32a |
| T251I + P587L | 168 ± 63a | 18.5 ± 7.4a | 0.11 ± 0.01a | 5a |
a p ≤ 0.05.
Physical Association with the p55 Accessory Subunit Is Unperturbed in the Pol γ Variants
Because failure of the Pol γ holoenzyme to assemble properly could emulate catalytic deficiency in vitro, we evaluated physical association between the accessory subunit and each catalytic subunit under stringent conditions in vitro. Polymerase activity was measured on poly(rA)·oligo(dT)12–18 with 25 μm dTTP, 220 mm NaCl, the indicated p140 subunit at 2.5 nm, and varying concentrations of p55. Because the isolated catalytic subunit is inactive at 220 mm NaCl, only activity of p140-p55 complexes is measured under these conditions (45). Binding isotherms were constructed from plots of polymerase activity measured at each concentration of p55, permitting calculation of a subunit dissociation constant, apparent Kd(p55), for each variant (Fig. 6, A–D). The WT enzyme had an apparent Kd(p55) of 0.35 ± 0.07 nm, with statistically identical values for the single mutants, T251I (apparent Kd(p55) of 0.43 ± 0.20 nm) and P587L (apparent Kd(p55) of 0.44 ± 0.10 nm) (Fig. 6E). Interestingly, despite critical disruptions in thermostability, exonuclease activity, and polymerase activity, the double mutant retained high binding affinity for p55 (apparent Kd(p55) of 0.08 ± 0.08 nm). To control for the nucleotide binding defect of T251I + P587L (Table 1), the assay was repeated with 10-fold higher dTTP, and physical association with p55 dimers did not change (data not shown). High affinity binding of Pol γ subunits suggests that the biochemical defects associated with these p140 variants are caused by subtle structural changes instead of gross structural alterations that would impair Pol γ holoenzyme assembly.
FIGURE 6.
All Pol γ variants physically interact with the p55 accessory subunit. Nucleotide incorporation was normalized to percentage of the maximum for each enzyme and plotted as a function of the p55 dimer concentration for WT (red circles) (A), T251I (blue squares) (B), P587L (orange diamonds) (C), and T251I + P587L (purple triangles) (D). Reactions also contained 220 mm NaCl to restrict activity to p140-p55 complexes, as described under “Experimental Procedures.” E, apparent equilibrium binding constants (Kd(p55)) for the Pol γ variants. All values are the average of three independent experiments with error expressed as S.D. and significance determined by Student's t test. *, p ≤ 0.05.
Primer Extension of the Pol γ Variants Is Impaired Even in the Presence of p55
To determine whether the strong physical interaction between the catalytic and accessory subunits translated into proper function of Pol γ while copying a natural DNA template, we compared activity of each Pol γ variant alone or reconstituted with p55 in gel-based primer extension assays under conditions that permit multiple binding events in vitro. WT Pol γ reactions utilized a bacteriophage M13-based natural ssDNA template under physiological NaCl and dNTP concentrations in the presence and absence of p55 without use of a DNA trap. Without p55 present, the WT catalytic subunit can bind the primed M13 ssDNA primer-template and can synthesize 50–100 nucleotides (nt) before dissociating from the DNA (37). The presence of p55 enhances the DNA binding affinity of the holozyme complex, and under a physiological salt concentration, p55 conveys a salt tolerance and stimulates processivity as much as 50-fold (6). WT functioned as expected in this assay with virtually complete extension of the 35-mer DNA primer in the presence of the accessory subunit (Fig. 7, compare lanes 2 and 3). Distinct pausing at known template secondary structures (∼85 and ∼125 nt on the gel) was evident, as depicted previously (16, 18, 37, 38). The abilities of T251I (Fig. 7, compare lanes 4 and 5) and P587L (Fig. 7, compare lanes 6 and 7) to extend the DNA primer in the absence of p55 were moderately inhibited as compared with WT. Similarly, the processivity of both T251I and P587L in the presence of p55 was less than WT, with slightly less activity for P587L (Fig. 7, compare lane 3 with lanes 5 and 7). Extension of the DNA primer by T251I + P587L was undetectable in the absence of p55 (Fig. 7, lane 8). Even in the presence of the accessory subunit, the double mutant did not produce long fragments, although a small quantity of primer extension products accumulated at the first major pause site at ∼85 nt (Fig. 7, lane 9). In general, the lengths of the primer extension products for all Pol γ variants were proportional to polymerase activity, DNA binding affinity, thermostability, and kinetic parameters described earlier.
FIGURE 7.

Processivity of Pol γ variants on primed M13 is critically impaired in T251I + P587L. Primer extension reactions were performed and analyzed by denaturing PAGE as described under “Experimental Procedures.” Briefly, all 20-min reactions were conducted at 37 °C under physiological salt (150 mm) in the absence or presence of p55 without the use of a DNA trap. The reactions for WT and each Pol γ variant contained the same concentration of p140 (5 nm) and p55 (10 nm) when present, 2 nm DNA primer, and 25 μm dNTP. Lane 1 excludes enzyme. Lanes 2 and 3, WT without and with p55, respectively. Lanes 4 and 5, T251I without and with p55. Lanes 6 and 7, P587L without and with p55. Lanes 8 and 9, T251I + P587L without and with p55. The gel is representative of three independent experiments.
Discussion
After A467T, G848S, and W748S mutations, the in cis T251I + P587L double mutation is the fourth most common mutant allele in human POLG (15). Despite the high prevalence of this allele in mitochondrial disease, particularly in PEO, a kinetic and biochemical analysis of the in cis T251I + P587L Pol γ had not been reported until this study. We specifically wanted to determine whether an individual amino acid substitution was sufficient to cause dysfunction in vitro or whether the double mutation was necessary, and we wished to correlate dysfunction in vitro with pathogenicity.
T251I Pol γ Mutation
The scientific literature contains one case report of mitochondrial disease in a 45-year-old female PEO patient bearing a POLG allele that was wild type at codon 587 but bore a T251I substitution. The patient was compound heterozygous at POLG and carried an in trans G848S substitution in the other POLG allele (31). G848S is a recessive mutation in which the presentation of symptoms and progression of disease appear to depend on the mutation in the other allele (17), which taken together suggests that an isolated T251I substitution may be a disease allele (31). Low phylogenetic conservation of Thr-251 and infrequent reports of isolated T251I without an in cis P587L mutation imply that phenotypic effects of T251I substitution are very rare, benign, or well tolerated. Our biochemical analysis found T251I to possess reduced exonuclease activity, lowered thermostability, and catalytic efficiency that was only 29% of WT, despite a strong DNA binding affinity and proper physical association with the p55 accessory subunit that were similar to WT.
Reduced exonuclease activity for an exonuclease domain mutation was unsurprising. In vitro, other exonuclease domain mutations in POLG have either increased exonuclease activity, as in the case of R232G/H, or decreased proofreading ability, as with S305R, G303R, and L304R (46, 47). Skeletal muscle mtDNA from PEO patients with exonuclease mutations (A189G, T408A, and T414G) had an increased frequency of random point mutations as compared with controls, which was attributed to reduced proofreading exonuclease activity (48). However, disease mutations in conserved exonuclease domain codons (L211P, Q264H, and R265L) in the MIP1 gene, which encodes the Saccharomyces cerevisiae ortholog of human Pol γ, did not affect exonuclease activity (49, 50). This may be because there is no accessory subunit in yeast (51). Similarly, exonuclease activity of human R232G/H substitutions was not increased in the absence of p55 (46). Additionally, the decreased thermostability and catalytic efficiency of T251I may be reflective of structural instability of the variant. However, protein structure appeared intact, as ascertained from predictable chromatographic behavior during purification and unhindered ability to bind DNA and to interact with the accessory subunit.
Structural insight also sheds light upon the proficiencies and incapacities of the T251I variant. Structures for the Pol γ holoenzyme (Fig. 8A) and Pol γ-DNA complex (Fig. 8B) were solved by the Yin laboratory (52, 53). Pol γ undergoes intra- and intersubunit conformational changes upon binding to primer-template DNA (53). The position of Thr-251 is readily apparent in the holoenzyme structure (Fig. 8, A and C). However, in the Pol γ-DNA complex structure, Thr-251 resides in a disordered portion and is not visible. To highlight its approximate position, the Val-249 and Gln-262 residues that flank the flexible loop containing T251I are labeled and provide a general idea of how Thr-251 moves upon binding DNA (Fig. 8, B and C). For example, the distance between Thr-251 in the unbound structure and residues Val-249 and Gln-262 in the DNA complex form is 20.8 and 24.5 Å, respectively. In the unbound form, the putative Thr-251 residue is not found in the DNA binding pocket and moves even further away from the DNA primer-template in the Pol γ-DNA complex (PyMOL Molecular Graphics System, version 1.8, Schrödinger, LLC, New York) (Fig. 8C). Further, Thr-251 is not located at the interface of p140 and p55. Therefore, the T251I mutation would not be predicted to interfere with DNA binding or interaction with p55. Additionally, the isoleucine substitution of threonine replaces one Cβ-branched amino acid with another, which results in comparable bulkiness near the protein backbone with parallel limitations to conformations that the main chain can adopt. However, the amino acid substitution changes the side chain from uncharged polar to nonpolar, which may discourage movement in the exonuclease domain of Pol γ should the residue encounter other nonpolar side chains during DNA binding. The DNA-bound structure also places the Thr-251 residue in a surface-exposed position, which favors an uncharged polar residue but not a nonpolar residue. Thus, a decrease in movement and an unfavorable surface-exposed position could partly contribute to a decrease in exonuclease activity, reduced catalytic efficiency, and protein instability with this variant.
FIGURE 8.
The Pol γ structures. Shown are the structures of Pol γ as a holoenzyme (Protein Data Bank entry 3IKM) (A) and in complex with DNA (Protein Data Bank entry 4ZTU) (B). The Thr-251 residue (dark red) (C) and Pro-587 residue (dark red) (D) in the holoenzyme (Pol γ backbone in gray) and when bound to DNA with the distances moved are shown. Gray, N terminus; blue, exonuclease domain; dark orange, intrinsic processivity subdomain of the linker region; light orange, accessory-interacting determinant subdomain of the linker region; cyan, polymerase domain; green, p55; magenta, DNA. All panels were made with the PyMOL Molecular Graphics System version 1.8 (Schrödinger, LLC, New York).
P587L Pol γ Mutation
The scientific literature describes three cases of PEO in which the P587L POLG substitution is not in cis with T251I (29–31). In each case, another mutation occurs in trans with P587L that could be contributing to or causing pathology. However, the high degree of phylogenetic conservation of P587L in vertebrates strongly supports the notion that P587L is a disease allele. Our biochemical analysis revealed that P587L has deficiencies in DNA binding, thermostability, exonuclease activity, kinetics parameters, and primer extension activity. Like T251I, P587L does not affect physical association between the catalytic and accessory subunit.
Again, examination of Pol γ structures helps to explain these biochemical shortcomings. The shift between the Cα-Cα measurement for Pro-587 for the holoenzyme and the Pol γ-DNA complex is 17.2 Å (Fig. 8, A, B, and D). In the holoenzyme, the Pro-587 residue is located within the DNA binding pocket. Therefore, Pro-587 needs to shift to accommodate DNA binding and in the Pol γ-DNA complex moves significantly closer to the p55 interface. When mutated, the substitution replaces the more rigid, ringed, rotomer-restricted proline with the more flexible, longer side chain of leucine. The rigidity of proline is frequently required to maintain the structural characteristics of a protein. Given the large movement that Pro-587 undergoes upon DNA binding, the loss of proline may thermodynamically favor or accommodate conformations less favorable for turnover. Indeed, this may cause instability and could lead to the observed changes in DNA binding affinity, primer extension activity, protein stability, and exonuclease activity. A Kd(p55) equivalent to WT, however, suggests no obstruction of binding to p55.
T251I + P587L Pol γ Mutation
Our biochemical analysis revealed that the individual T251I and P587L mutations negatively affected the function of Pol γ in vitro, with P587L causing more deleterious effects. Together, the mutations act synergistically along all measured parameters and cause more severe dysfunction than either mutation alone. For instance, the DNA binding affinity of T251I + P587L was 3-fold weaker than WT, whereas binding by P587L was 2-fold lower than WT, and T251I had no impaired DNA binding. The reduced ability of T251I + P587L to bind DNA, in combination with the intrinsic deficiency in T251I exonuclease activity, probably leads to poor proofreading and repair abilities. T251I + P587L was also found to be remarkably sensitive to heat inactivation. Early indications of protein instability were inferred during protein purification, when only low quantities of protein were recovered during elution from the MonoQ column as compared with the yields for the WT and the single mutant variants. Functionally, these weaknesses, in conjunction with a profound nucleotide binding deficiency, caused remarkably inefficient catalysis (∼5% of WT) and DNA processivity for T251I + P587L, although none of these failings were due to diminished intersubunit affinity for p55.
Our results reveal that isolated T251I and P587L substitutions in POLG individually hamper the in vitro functioning of the enzyme. We infer that individuals bearing either mutation alone have not been identified because they may not present with any pathology. Conversely, T251I + P587L is a profoundly impaired enzyme in vitro, suggesting synergistic dysfunction when the mutations present in cis. As a recessive mutation in vivo, the presence of T251I + P587L on one allele does not result in disease because the WT allele provides sufficient polymerase function for survival. Therefore, we suggest that pathogenicity only becomes evident in those patients carrying this recessive combination mutation in trans with deleterious mutations on the other POLG allele. For instance, two female infants that were compound heterozygous for T251I + P587L and R232G presented with a severe phenotype in infancy and died before 16 months of age (21, 35). The R232G substitution causes decreased polymerase and increased exonuclease activities with decreased selectivity for mismatches (46). Conversely, no pattern emerges with G848S, a POLG mutation in the highly conserved thumb subdomain with extreme deficiencies in polymerase activity and DNA binding in vitro (17). Individuals with the T251I + P587L in trans with G848S include a 75-year-old man with severe PEO and myopathy who first presented clinically at the age of 55 (54); an 80-year-old man with ptosis, SANDO, and myopathy who was first seen at the age of 73 (55); and a 6-month-old infant with Alpers syndrome (20). Because of the highly dysfunctional nature of T251I + P587L, patients homozygous for the combination mutation would be predicted to present with a severe phenotype and/or early age of onset. However, identified patients have a midlife age of onset with a mild phenotype (22, 24, 32). Taken together, we suggest that factors other than multiple POLG mutations contribute to the severity and age of onset of mitochondrial disease. Possible contributing factors include disease-causing mutations in other nuclear genes; altered interactions with other mtDNA replication proteins, such as the mitochondrial Twinkle helicase or the single-stranded DNA-binding protein; the inherited level of somatic mtDNA heteroplasmy; epigenetic factors; and gene-environment interactions, coined ecogenetics (18, 22, 56, 57).
Gene-environment interactions are not unprecedented. Valproate, a first-line anticonvulsant, caused hepatotoxicity in a 2-year-old boy with POLG mutations (58). A sequential study of subjects enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2008 found that heterozygous genetic variation in POLG was strongly associated with valproate-induced hepatotoxicity (59). Also, chain-terminating nucleoside reverse transcriptase inhibitors used to combat HIV infection inhibit Pol γ during mtDNA replication (60). Genetic polymorphisms in POLG also explain the variation in mitochondrial toxicity in HIV-infected patients (61, 62). Other viruses, such as human herpesvirus 6, caused encephalitis in two patients with mutations in POLG and exacerbated the Alpers phenotype, contributing to a more rapid clinical deterioration (63). Although not tied to specific POLG mutations, mitochondria are susceptible to environmental toxicants, such as heavy metals and pesticides (64, 65), which leads to questioning whether exposure to environmental contaminants could contribute to altering the age of onset and severity of POLG diseases. Indeed, we utilized S. cerevisiae as a model system to demonstrate that methyl methanesulfonate-induced mutagenesis of mtDNA is increased 30-fold in certain MIP1 disease mutants relative to WT (66). It is critical that future studies continue to identify mechanisms by which mutated forms of human POLG interact with environmental stressors to alter severity of the phenotype and age of onset of mitochondrial diseases.
Experimental Procedures
Construction, Expression, and Purification of Pol γ Protein Variants and p55
WT POLG cDNA with a His6 affinity tag and without a mitochondrial targeting sequence was cloned into the pVL1393 baculovirus transfer vector, which served as the PCR template (43). The T251I, P587L, and T251I + P587L mutations were generated using the QuikChange site-directed mutagenesis kit (Stratagene) using the following mutagenic primers: for T251I, 5′-CCC CTG GAG GTC CCT ATT GGT GCC AGC AGC-3′ (forward) and 5′-GCT GCT GGC ACC AAT AGG GAC CTC CAG GGG-3′ (reverse); for P587L, 5′-GAC CCT GCA TGG ACC CTG GGC CCC AGC CTC CTC-3′ (forward) and 5′-GAG GAG GCT GGG GCC CAG GGT CCA TGC AGG GTC-3′ (reverse) (Integrated DNA Technologies). Nucleotides changed by site-directed mutagenesis are underlined. The mutations were confirmed by DNA sequencing of the Pol γ insert in the baculovirus transfer vector. Recombinant baculoviruses were generated by cotransfection of the transfer plasmids with BacPAK6 viral DNA as outlined by the manufacturer (Clontech). Virus stocks were amplified, and recombinant proteins were expressed in Sf9 insect cells grown in suspension at 27 °C in SF900 III medium (Invitrogen). Proteins were purified to homogeneity and stored as described previously (37–39). The His6 affinity-tagged p55 accessory subunit was expressed in Escherichia coli, purified to homogeneity, and stored as reported previously (39, 67).
DNA Binding Assay
The apparent disassociation constant, Kd(DNA), for WT and each mutant variant of Pol γ was determined by electrophoretic mobility shift assay (EMSA). Primer-template substrate was constructed by hybridizing and annealing 3′-FITC-labeled oligonucleotide (5′-GCA GGA GGT GGC GTC GGG TGG ACG GGT GGA TTG AAA TTT AGG CTG GCA CGG TCT-3′) to unlabeled complement (5′-AGA CCG TGC CAG CCT AAA TTT CAA TCC AAG GTC TCG ACT AAC TCT AGT CGT TGT-3′) (Integrated DNA Technologies) in a 1:1.2 ratio, creating a fluorescently labeled, double-stranded, forked, 54-mer DNA substrate. The DNA was purified on an S200 column, and concentration was determined on an ND 1000 spectrophotometer (NanoDrop). Reaction mixtures (10 μl) were assembled on ice and contained 10 mm Tris-HCl (pH 8.0); 0.2 mg/ml acetylated BSA; 2 mm DTT; 10 nm primer-template; and a 0, 12.5, 25, 50, 75, 100, 105, 125, 150, 175, 200, 225, or 250 nm concentration of the indicated Pol γ protein. After a 5-min incubation, 2 μl of 5× loading buffer (10 mm Tris-HCl (pH 8.0), 0.1% bromphenol blue, and 50% glycerol) was added to the reaction mixture. Protein-bound and free DNA were resolved by electrophoresis for 1 h at 180 V at 4 °C through 8% TBE native polyacrylamide gel (Invitrogen) in 0.5× TBE. Gels were imaged on a Typhoon 9400 PhosphorImager (GE Healthcare), and band intensity was quantified by NIH Image J32 version 1.5 software.
Thermostability
The holoenzymes were reconstituted on ice in a 1:2 molar ratio of Pol γ to p55 as described previously (6). Holoenzymes (10 μl) were placed at 37 °C for 0, 1, 2, 3, 4, 5, 6, 7.5, 9, 13, 17, 21, 25, 30, 35, 40, or 45 min. Reactions (50 μl) containing 25 mm HEPES-KOH (pH 7.5), 2.5 mm 2-mercaptoethanol, 0.5 mm MnCl2, 200 μg/ml heat-treated BSA, 75 mm NaCl, 300 μm dTTP, 16 μCi/ml [α-32P]dTTP, 50 μg/ml poly(rA)·oligo(dT)12–18 primer-template, and 5 μl of heat-treated holoenzyme were incubated at 37 °C for 10 min and processed as described previously (37). Incubation at time 0 for each variant was set to 100%. Half-life was determined by fitting activity remaining at the designated times to an equation for exponential decay.
Exonuclease Assays
Exonuclease activity was determined as described with some modification (37). Here, we examined the degradation of a 5′- γ-32P-labeled 35-mer single-stranded M13 primer (5′-CCA GTG CCA AGC TTG CAT GCC TGC AGG TCG ACT CT-3′) (Integrated DNA Technologies). Reaction mixtures (10 μl) contained 25 mm HEPES (pH 8.0), 2 mm 2-mercaptoethanol, 50 μg/ml heat-treated BSA, 0.1 mm EDTA, 50 nm primer, and 2 nm p140. Reactions were incubated at 37 °C for 1 min before 5 mm MgCl2 was added to start the reaction. Reactions were stopped with 10 μl of formamide solution (95% deionized formamide, 0.01 m EDTA, 0.1% bromphenol blue, and 0.1% xylene cyanol) after 0, 0.5, 1, 1.5, 2, 2.5, and 3 min. Products were analyzed by denaturing 12% polyacrylamide gel electrophoresis and quantified with a Typhoon 9400 PhosphorImager (GE Healthcare) and NIH Image J32 version 1.5 software to determine rate of excision (kexo) of the 3′-primer terminus from each substrate. Enzyme concentrations for each Pol γ variant were determined to be within the linear range of the reaction. Final enzyme concentrations were 0.3 nm WT, 1.25 nm T251I, 1.5 nm P587L, and 3.0 nm T251I + P587L.
Steady-state Kinetics
DNA polymerase activity on poly(dA)·oligo(dT)12–18 was determined in the presence of p55 as described previously (6, 39). Briefly, reaction mixtures (50 μl) were assembled on ice and contained 25 mm Tris-HCl (pH 8.0), 1 mm 2-mercaptoethanol, 5 mm MgCl2, 200 μg/ml heat-treated BSA, 100 mm NaCl, 16 μCi/ml [α-32P]dTTP, 50 μg/ml poly(dA)·oligo(dT)12–18 primer-template (equimolar dA/dT ratio), varying concentrations of dTTP (0, 0.5, 1, 1.5, 2, 3, 5, 10, 15, 20, and 25 μm), and a fixed concentration of holoenzyme (1 nm p140 + 2 nm p55). After incubation at 37 °C for 0, 3, 6, 8, and 10 min, reactions were stopped with 0.2 ml of 1 mg/ml BSA in 0.1 m NaPPi and 1 ml of cold 10% TCA. The mixture was filtered through Whatman GF/C filters, washed with 1 n HCl, rinsed with 100% ethanol, and dried before TCA-insoluble radioactivity was determined by liquid scintillation counting. Steady-state kinetic values were determined as described (6).
Binding Affinity for p55
Physical association between the catalytic and accessory subunits was assessed in reactions (50 μl) containing 25 mm HEPES-KOH (pH 7.5), 2.5 mm 2-mercaptoethanol, 0.5 mm MnCl2, 200 μg/ml heat-treated BSA, 220 mm NaCl, 25 μm dTTP, 16 μCi/ml [α-32P]dTTP, 50 μg/ml poly(rA)·oligo(dT)12–18 primer-template, 2.5 nm p140, and varying concentrations of p55 (0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 7.5, 10, 15, 20, and 25 nm). Reactions were incubated at 37 °C for 9 min and processed as described above. Maximal polymerase activity for each variant was set at 100%, and apparent Kd(p55) values were derived by nonlinear regression analysis of DNA polymerase activity plotted against the concentration of p55 dimers, as described (40).
Processivity Analysis
Processivity of DNA synthesis for each Pol γ form was estimated with primer extension reactions in vitro, which utilized γ-32P-end-labeled, singly primed M13 DNA substrate as indicated previously (6) without the preincubation step and under conditions of 150 mm NaCl without the addition of a DNA trap. Samples were analyzed on 12% denaturing polyacrylamide gels.
Author Contributions
K. L. D. and M. J. L. designed the experiments. K. L. D. and K. E. H. performed the experiments. K. L. D. wrote the manuscript with input from all authors. M. J. L. and W. C. C. managed the project.
Acknowledgments
We thank Dr. Samuel Gattis for initiating this project and Drs. Kasia Bebenek and Leroy Worth for critical reading of the manuscript.
This study was supported by the Intramural Research Program of the NIEHS, National Institutes of Health, Grant ES 065078. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- mtDNA
- mitochondrial DNA
- Pol γ
- polymerase γ
- PEO
- progressive external ophthalmoplegia
- ANS
- ataxia neuropathy syndromes
- nt
- nucleotide(s).
References
- 1. Bebenek K., and Kunkel T. A. (2004) Functions of DNA polymerases. Adv. Protein. Chem. 69, 137–165 [DOI] [PubMed] [Google Scholar]
- 2. Ropp P. A., and Copeland W. C. (1996) Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase γ. Genomics 36, 449–458 [DOI] [PubMed] [Google Scholar]
- 3. Sweasy J. B., Lauper J. M., and Eckert K. A. (2006) DNA polymerases and human diseases. Radiat. Res. 166, 693–714 [DOI] [PubMed] [Google Scholar]
- 4. Graziewicz M. A., Longley M. J., and Copeland W. C. (2006) DNA polymerase γ in mitochondrial DNA replication and repair. Chem. Rev. 106, 383–405 [DOI] [PubMed] [Google Scholar]
- 5. Kaguni L. S. (2004) DNA polymerase γ, the mitochondrial replicase. Annu. Rev. Biochem. 73, 293–320 [DOI] [PubMed] [Google Scholar]
- 6. Lim S. E., Longley M. J., and Copeland W. C. (1999) The mitochondrial p55 accessory subunit of human DNA polymerase γ enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. J. Biol. Chem. 274, 38197–38203 [DOI] [PubMed] [Google Scholar]
- 7. Young M. J., Humble M. M., DeBalsi K. L., Sun K. Y., and Copeland W. C. (2015) POLG2 disease variants: analyses reveal a dominant negative heterodimer, altered mitochondrial localization and impaired respiratory capacity. Hum. Mol. Genet. 24, 5184–5197 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Johnson A. A., Tsai Yc., Graves S. W., and Johnson K. A. (2000) Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. Biochemistry 39, 1702–1708 [DOI] [PubMed] [Google Scholar]
- 9. Tuppen H. A., Blakely E. L., Turnbull D. M., and Taylor R. W. (2010) Mitochondrial DNA mutations and human disease. Biochim. Biophys. Acta 1797, 113–128 [DOI] [PubMed] [Google Scholar]
- 10. Copeland W. C. (2014) Defects of mitochondrial DNA replication. J. Child. Neurol. 29, 1216–1224 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. DeBalsi K. L., Hoff K. E., and Copeland W. C. (2017) Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. Ageing Res. Rev. 33, 89–104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Longley M. J., Graziewicz M. A., Bienstock R. J., and Copeland W. C. (2005) Consequences of mutations in human DNA polymerase γ. Gene 354, 125–131 [DOI] [PubMed] [Google Scholar]
- 13. Chan S. S., and Copeland W. C. (2009) DNA polymerase γ and mitochondrial disease: understanding the consequence of POLG mutations. Biochim. Biophys. Acta 1787, 312–319 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Copeland W. C. (2010) The mitochondrial DNA polymerase in health and disease. Subcell. Biochem. 50, 211–222 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Tang S., Wang J., Lee N. C., Milone M., Halberg M. C., Schmitt E. S., Craigen W. J., Zhang W., and Wong L. J. (2011) Mitochondrial DNA polymerase {gamma} mutations: an ever expanding molecular and clinical spectrum. J. Med. Genet. 48, 669–681 [DOI] [PubMed] [Google Scholar]
- 16. Chan S. S. L., Longley M. J., and Copeland W. C. (2005) The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. J. Biol. Chem. 280, 31341–31346 [DOI] [PubMed] [Google Scholar]
- 17. Kasiviswanathan R., Longley M. J., Chan S. S., and Copeland W. C. (2009) Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in MtDNA replication. J. Biol. Chem. 284, 19501–19510 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Chan S. S. L., Longley M. J., and Copeland W. C. (2006) Modulation of the W748S mutation in DNA polymerase γ by the E1143G polymorphism in mitochondrial disorders. Hum. Mol. Genet. 15, 3473–3483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Scuderi C., Borgione E., Castello F., Lo Giudice M., Santa Paola S., Giambirtone M., Di Blasi F. D., Elia M., Amato C., Città S., Gagliano C., Barbarino G., Vitello G. A., and Musumeci S. A. (2015) The in cis T251I and P587L POLG1 base changes: description of a new family and literature review. Neuromuscul. Disord. 25, 333–339 [DOI] [PubMed] [Google Scholar]
- 20. Wong L. J., Naviaux R. K., Brunetti-Pierri N., Zhang Q., Schmitt E. S., Truong C., Milone M., Cohen B. H., Wical B., Ganesh J., Basinger A. A., Burton B. K., Swoboda K., Gilbert D. L., Vanderver A., et al. (2008) Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum. Mutat. 29, E150–E172 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Ferrari G., Lamantea E., Donati A., Filosto M., Briem E., Carrara F., Parini R., Simonati A., Santer R., and Zeviani M. (2005) Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 128, 723–731 [DOI] [PubMed] [Google Scholar]
- 22. Horvath R., Hudson G., Ferrari G., Fütterer N., Ahola S., Lamantea E., Prokisch H., Lochmüller H., McFarland R., Ramesh V., Klopstock T., Freisinger P., Salvi F., Mayr J. A., Santer R., Tesarova M., Zeman J., et al. (2006) Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain 129, 1674–1684 [DOI] [PubMed] [Google Scholar]
- 23. Harris M. O., Walsh L. E., Hattab E. M., and Golomb M. R. (2010) Is it ADEM, POLG, or both? Arch. Neurol. 67, 493–496 [DOI] [PubMed] [Google Scholar]
- 24. Stewart J. D., Tennant S., Powell H., Pyle A., Blakely E. L., He L., Hudson G., Roberts M., du Plessis D., Gow D., Mewasingh L. D., Hanna M. G., Omer S., Morris A. A., Roxburgh R., et al. (2009) Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children. J. Med. Genet. 46, 209–214 [DOI] [PubMed] [Google Scholar]
- 25. Van Goethem G., Schwartz M., Löfgren A., Dermaut B., Van Broeckhoven C., and Vissing J. (2003) Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur. J. Hum. Genet. 11, 547–549 [DOI] [PubMed] [Google Scholar]
- 26. Di Fonzo A., Bordoni A., Crimi M., Sara G., Bo R. D., Bresolin N., and Comi G. P. (2003) POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions. Hum. Mutat. 22, 498–499 [DOI] [PubMed] [Google Scholar]
- 27. Tzoulis C., Papingji M., Fiskestrand T., Roste L. S., and Bindoff L. A. (2009) Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. Acta Neurol. Scand. Suppl. 10.1111/j.1600-0404.2009.01212.x [DOI] [PubMed] [Google Scholar]
- 28. Blok M. J., van den Bosch B. J., Jongen E., Hendrickx A., de Die-Smulders C. E., Hoogendijk J. E., Brusse E., de Visser M., Poll-The B. T., Bierau J., de Coo I. F., and Smeets H. J. (2009) The unfolding clinical spectrum of POLG mutations. J. Med. Genet. 46, 776–785 [DOI] [PubMed] [Google Scholar]
- 29. Lamantea E., Tiranti V., Bordoni A., Toscano A., Bono F., Servidei S., Papadimitriou A., Spelbrink H., Silvestri L., Casari G., Comi G. P., and Zeviani M. (2002) Mutations of mitochondrial DNA polymerase γ are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann. Neurol. 52, 211–219 [DOI] [PubMed] [Google Scholar]
- 30. Agostino A., Valletta L., Chinnery P. F., Ferrari G., Carrara F., Taylor R. W., Schaefer A. M., Turnbull D. M., Tiranti V., and Zeviani M. (2003) Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 60, 1354–1356 [DOI] [PubMed] [Google Scholar]
- 31. Rouzier C., Chaussenot A., Serre V., Fragaki K., Bannwarth S., Ait-El-Mkadem S., Attarian S., Kaphan E., Cano A., Delmont E., Sacconi S., Mousson de Camaret B., Rio M., Lebre A. S., Jardel C., et al. (2014) Quantitative multiplex PCR of short fluorescent fragments for the detection of large intragenic POLG rearrangements in a large French cohort. Eur. J. Hum. Genet. 22, 542–550 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Lamantea E., and Zeviani M. (2004) Sequence analysis of familial PEO shows additional mutations associated with the 752C→T and 3527C→T changes in the POLG1 gene. Ann. Neurol. 56, 454–455 [DOI] [PubMed] [Google Scholar]
- 33. Filosto M., Mancuso M., Nishigaki Y., Pancrudo J., Harati Y., Gooch C., Mankodi A., Bayne L., Bonilla E., Shanske S., Hirano M., and DiMauro S. (2003) Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase γ. Arch. Neurol. 60, 1279–1284 [DOI] [PubMed] [Google Scholar]
- 34. González-Vioque E., Blázquez A., Fernández-Moreira D., Bornstein B., Bautista J., Arpa J., Navarro C., Campos Y., Fernández-Moreno M. A., Garesse R., Arenas J., and Martín M. A. (2006) Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population. Arch. Neurol. 63, 107–111 [DOI] [PubMed] [Google Scholar]
- 35. Ashley N., O'Rourke A., Smith C., Adams S., Gowda V., Zeviani M., Brown G. K., Fratter C., and Poulton J. (2008) Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations. Hum. Mol. Genet. 17, 2496–2506 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Farnum G. A., Nurminen A., and Kaguni L. S. (2014) Mapping 136 pathogenic mutations into functional modules in human DNA polymerase γ establishes predictive genotype-phenotype correlations for the complete spectrum of POLG syndromes. Biochim. Biophys. Acta 1837, 1113–1121 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Longley M. J., Ropp P. A., Lim S. E., and Copeland W. C. (1998) Characterization of the native and recombinant catalytic subunit of human DNA polymerase γ: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37, 10529–10539 [DOI] [PubMed] [Google Scholar]
- 38. Graziewicz M. A., Longley M. J., Bienstock R. J., Zeviani M., and Copeland W. C. (2004) Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat. Struct. Mol. Biol. 11, 770–776 [DOI] [PubMed] [Google Scholar]
- 39. Kasiviswanathan R., Longley M. J., Young M. J., and Copeland W. C. (2010) Purification and functional characterization of human mitochondrial DNA polymerase γ harboring disease mutations. Methods 51, 379–384 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Heyduk T., and Lee J. C. (1990) Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc. Natl. Acad. Sci. U.S.A. 87, 1744–1748 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Longley M. J., and Mosbaugh D. W. (1991) Properties of the 3′ to 5′ exonuclease associated with porcine liver DNA polymerase γ: substrate specificity, product analysis, inhibition, and kinetics of terminal excision. J. Biol. Chem. 266, 24702–24711 [PubMed] [Google Scholar]
- 42. Kasiviswanathan R., and Copeland W. C. (2011) Biochemical analysis of the G517V POLG variant reveals wild-type like activity. Mitochondrion 11, 929–934 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Lim S. E., and Copeland W. C. (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase γ. J. Biol. Chem. 276, 23616–23623 [DOI] [PubMed] [Google Scholar]
- 44. Kasiviswanathan R., Minko I. G., Lloyd R. S., and Copeland W. C. (2013) Translesion synthesis past acrolein-derived DNA adducts by human mitochondrial DNA polymerase γ. J. Biol. Chem. 288, 14247–14255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Young M. J., Longley M. J., Li F. Y., Kasiviswanathan R., Wong L. J., and Copeland W. C. (2011) Biochemical analysis of human POLG2 variants associated with mitochondrial disease. Hum. Mol. Genet. 20, 3052–3066 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Lee Y. S., Johnson K. A., Molineux I. J., and Yin Y. W. (2010) A single mutation in human mitochondrial DNA polymerase pol γA affects both polymerization and proofreading activities, but only as a holoenzyme. J. Biol. Chem. 285, 28105–28116 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Macao B., Uhler J. P., Siibak T., Zhu X., Shi Y., Sheng W., Olsson M., Stewart J. B., Gustafsson C. M., and Falkenberg M. (2015) The exonuclease activity of DNA polymerase γ is required for ligation during mitochondrial DNA replication. Nat. Commun. 6, 7303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Del Bo R., Bordoni A., Sciacco M., Di Fonzo A., Galbiati S., Crimi M., Bresolin N., and Comi G. P. (2003) Remarkable infidelity of polymerase γA associated with mutations in POLG1 exonuclease domain. Neurology 61, 903–908 [DOI] [PubMed] [Google Scholar]
- 49. Szczepanowska K., and Foury F. (2010) A cluster of pathogenic mutations in the 3′–5′ exonuclease domain of DNA polymerase γ defines a novel module coupling DNA synthesis and degradation. Hum. Mol. Genet. 19, 3516–3529 [DOI] [PubMed] [Google Scholar]
- 50. Stumpf J. D., and Copeland W. C. (2011) Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations. Cell Mol. Life Sci. 68, 219–233 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Lucas P., Laquel-Robert P., Plissonneau J., Schaeffer J., Tarrago-Litvak L., and Castroviejo M. (1997) A second DNA polymerase activity in yeast mitochondria. C. R. Acad. Sci. III 320, 299–305 [DOI] [PubMed] [Google Scholar]
- 52. Lee Y. S., Kennedy W. D., and Yin Y. W. (2009) Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell 139, 312–324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Szymanski M. R., Kuznetsov V. B., Shumate C., Meng Q., Lee Y. S., Patel G., Patel S., and Yin Y. W. (2015) Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase. EMBO J. 34, 1959–1970 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Kollberg G., Jansson M., Pérez-Bercoff A., Melberg A., Lindberg C., Holme E., Moslemi A. R., and Oldfors A. (2005) Low frequency of mtDNA point mutations in patients with PEO associated with POLG1 mutations. Eur. J. Hum. Genet. 13, 463–469 [DOI] [PubMed] [Google Scholar]
- 55. Weiss M. D., and Saneto R. P. (2010) Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous POLG mutations. Muscle Nerve 41, 882–885 [DOI] [PubMed] [Google Scholar]
- 56. Saneto R. P., and Naviaux R. K. (2010) Polymerase γ disease through the ages. Dev. Disabil. Res. Rev. 16, 163–174 [DOI] [PubMed] [Google Scholar]
- 57. Cohen B. H., and Naviaux R. K. (2010) The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 51, 364–373 [DOI] [PubMed] [Google Scholar]
- 58. McFarland R., Hudson G., Taylor R. W., Green S. H., Hodges S., McKiernan P. J., Chinnery P. F., and Ramesh V. (2008) Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase γ (POLG1). Arch. Dis. Child. 93, 151–153 [DOI] [PubMed] [Google Scholar]
- 59. Stewart J. D., Horvath R., Baruffini E., Ferrero I., Bulst S., Watkins P. B., Fontana R. J., Day C. P., and Chinnery P. F. (2010) Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52, 1791–1796 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Lim S. E., Ponamarev M. V., Longley M. J., and Copeland W. C. (2003) Structural determinants in human DNA polymerase γ account for mitochondrial toxicity from nucleoside analogs. J. Mol. Biol. 329, 45–57 [DOI] [PubMed] [Google Scholar]
- 61. Chiappini F., Teicher E., Saffroy R., Debuire B., Vittecoq D., and Lemoine A. (2009) Relationship between polymerase γ (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr. HIV Res. 7, 244–253 [DOI] [PubMed] [Google Scholar]
- 62. Bailey C. M., Kasiviswanathan R., Copeland W. C., and Anderson K. S. (2009) R964C mutation of DNA polymerase γ imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob. Agents Chemother. 53, 2610–2612 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Al-Zubeidi D., Thangarajh M., Pathak S., Cai C., Schlaggar B. L., Storch G. A., Grange D. K., and Watson M. E. Jr. (2014) Fatal human herpesvirus 6-associated encephalitis in two boys with underlying POLG mitochondrial disorders. Pediatr. Neurol. 51, 448–452 [DOI] [PubMed] [Google Scholar]
- 64. Meyer J. N., Leung M. C., Rooney J. P., Sendoel A., Hengartner M. O., Kisby G. E., and Bess A. S. (2013) Mitochondria as a target of environmental toxicants. Toxicol. Sci. 134, 1–17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Caito S. W., and Aschner M. (2015) Mitochondrial redox dysfunction and environmental exposures. Antioxid. Redox Signal. 23, 578–595 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Stumpf J. D., and Copeland W. C. (2014) MMS exposure promotes increased MtDNA mutagenesis in the presence of replication-defective disease-associated DNA polymerase γ variants. PLoS Genet. 10, e1004748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Longley M. J., Clark S., Yu Wai Man C., Hudson G., Durham S. E., Taylor R. W., Nightingale S., Turnbull D. M., Copeland W. C., and Chinnery P. F. (2006) Mutant POLG2 disrupts DNA polymerase γ subunits and causes progressive external ophthalmoplegia. Am. J. Hum. Genet. 78, 1026–1034 [DOI] [PMC free article] [PubMed] [Google Scholar]




